These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 12435056)

  • 1. Technology evaluation: PROSTVAC, Therion.
    Doehn C; Jocham D
    Curr Opin Mol Ther; 2002 Oct; 4(5):528-34. PubMed ID: 12435056
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug evaluation: Therion's rV-PSA-TRICOM + rF-PSA-TRICOM prime-boost prostate cancer vaccine.
    Doehn C; Kausch I; Böhmer T; Sommerauer M; Jocham D
    Curr Opin Mol Ther; 2007 Apr; 9(2):183-9. PubMed ID: 17458173
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Technology evaluation: Onyvax-P, Onyvax.
    Doehn C; Böhmer T; Jocham D
    Curr Opin Mol Ther; 2005 Oct; 7(5):511-9. PubMed ID: 16248287
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Technology evaluation: ALVAC-CEA/B7.1, Aventis Pasteur/Therion.
    Ertl HC
    Curr Opin Mol Ther; 2002 Dec; 4(6):601-5. PubMed ID: 12596363
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Technology evaluation: DCVax, Northwest Biotherapeutics.
    Knutson KL
    Curr Opin Mol Ther; 2002 Aug; 4(4):403-7. PubMed ID: 12222879
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of high risk metastatic prostate cancer: the case for novel therapies.
    Brand TC; Tolcher AW
    J Urol; 2006 Dec; 176(6 Pt 2):S76-80; discussion S81-2. PubMed ID: 17084174
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Technology evaluation: TroVax, Oxford BioMedica.
    Reinis M
    Curr Opin Mol Ther; 2004 Aug; 6(4):436-42. PubMed ID: 15468602
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Strategies for the development of PSA-based vaccines for the treatment of advanced prostate cancer.
    Arlen PM; Gulley JL; Tsang KY; Schlom J
    Expert Rev Vaccines; 2003 Aug; 2(4):483-93. PubMed ID: 14711334
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Technology evaluation: APC-80200, Dendreon.
    Rice A; Hart D
    Curr Opin Mol Ther; 2002 Oct; 4(5):523-7. PubMed ID: 12435055
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GVAX (Cell Genesys).
    Dummer R
    Curr Opin Investig Drugs; 2001 Jun; 2(6):844-8. PubMed ID: 11572668
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer.
    Gulley JL; Arlen PM; Bastian A; Morin S; Marte J; Beetham P; Tsang KY; Yokokawa J; Hodge JW; Ménard C; Camphausen K; Coleman CN; Sullivan F; Steinberg SM; Schlom J; Dahut W
    Clin Cancer Res; 2005 May; 11(9):3353-62. PubMed ID: 15867235
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostate cancer vaccines in clinical trials.
    Lubaroff DM
    Expert Rev Vaccines; 2012 Jul; 11(7):857-68. PubMed ID: 22913261
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Vaccine therapy of prostate cancer].
    Doehn C; Böhmer T; Sommerauer M; Kausch I; Jocham D
    Aktuelle Urol; 2005 Sep; 36(5):407-16. PubMed ID: 16163603
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PSA-based vaccines for the treatment of prostate cancer.
    Madan RA; Gulley JL; Arlen PM
    Expert Rev Vaccines; 2006 Apr; 5(2):199-209. PubMed ID: 16608420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vaccine therapy for prostate cancer.
    Sonpavde G; Spencer DM; Slawin KM
    Urol Oncol; 2007; 25(6):451-9. PubMed ID: 18047951
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of PROSTVAC immunotherapy in prostate cancer.
    Singh P; Pal SK; Alex A; Agarwal N
    Future Oncol; 2015; 11(15):2137-48. PubMed ID: 26235179
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tribulations or triumphs in prostate cancer immunotherapy: on the road to victory?
    Slovin SF
    Expert Rev Anticancer Ther; 2008 Mar; 8(3):465-74. PubMed ID: 18366293
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Technology evaluation: HSPPC-96, antigenics.
    Minev BR
    Curr Opin Mol Ther; 2003 Dec; 5(6):680-7. PubMed ID: 14755896
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Special report: vaccines for the treatment of prostate cancer.
    Technol Eval Cent Assess Program Exec Summ; 2010 Apr; 24(6):1-2. PubMed ID: 20575182
    [No Abstract]   [Full Text] [Related]  

  • 20. Systemic therapeutic strategies for prostate cancer.
    Nelson WG
    Clin Adv Hematol Oncol; 2005 Aug; 3(8):619-21. PubMed ID: 16167046
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.